News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Release: Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology



6/13/2012 10:36:23 AM

PARIS--(BUSINESS WIRE)--AB Science SA (Paris:AB)(NYSE-Euronext-FR0010557264-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis. The article, ‘Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study’, is freely accessible online from BioMed Central's peer-reviewed journal BMC Neurology (http://www.biomedcentral.com/1471-2377/12/36/abstract).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES